AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vera-Cabrera, L.
Right arrow Articles by Molina-Torres, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vera-Cabrera, L.
Right arrow Articles by Molina-Torres, C.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 2005, p. 4351-4353, Vol. 49, No. 10
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.10.4351-4353.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

In Vitro Susceptibility of Mycobacterium tuberculosis Clinical Isolates to Garenoxacin and DA-7867

Lucio Vera-Cabrera,1* Jorge Castro-Garza,2 Adrian Rendon,3 Jorge Ocampo-Candiani,1 Oliverio Welsh,1 Sung Hak Choi,4 Kym Blackwood,5 and Carmen Molina-Torres1

Servicio de Dermatología, Hospital Universitario "José E. González," Monterrey, N. L., México 64460,1 División de Biología Celular y Molecular, Centro de Investigación Biomédica del Noreste, IMSS, Monterrey, N. L., México,2 Servicio de Neumología, Hospital Universitario "José E. González," Monterrey, N. L., México 64460,3 Research Laboratory, Dong-A Pharmaceutical Co., Ltd., Yongin, Korea,4 National Microbiology Laboratory, Health Canada Canadian Science Centre for Human and Animal Health, Winnipeg, Canada5

Received 1 February 2005/ Returned for modification 8 April 2005/ Accepted 23 June 2005

The in vitro activities of DA-7867, a novel oxazolidinone, and garenoxacin (BMS-284756) were compared to those of linezolid in 67 susceptible and drug-resistant clinical isolates of Mycobacterium tuberculosis. DA-7867 was the most active drug with an MIC90 of 0.125 µg/ml, compared to the MIC90s of 4 µg/ml of garenoxacin and 2 µg/ml of linezolid.

* Corresponding author. Mailing address: Servicio de Dermatología, Hospital Universitario, "José E. González," Madero y Gonzalitos, Col. Mitras Centro, Monterrey, N. L., México. Phone: (5281) 8348-0383. Fax: (5281) 8348-4407. E-mail: luvera_99{at}yahoo.com.

Antimicrobial Agents and Chemotherapy, October 2005, p. 4351-4353, Vol. 49, No. 10
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.10.4351-4353.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2005 by the American Society for Microbiology. All rights reserved.